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lzheimer disease (AD) is characterized by extracellular
accumulation of plaques, which are aggregates of amyloid-β
(Aβ) peptides derived from proteolytic cleavages of amyloid precursor protein (APP), and intracellular accumulation of hyperphosphorylated tau (1). APP can be cleaved via the α- or the
β-secretase pathways (2). The β-secretase pathway, but not the
α-secretase pathway, generates Aβ from APP. Cholesterol content
in cells can affect the production of Aβ, in part by its ability to
modulate the enzyme activities of various secretases in cell
membranes (3). Cholesterol has also been implicated in the
pathogenesis of AD via other mechanisms (4–6).
In the brain, cholesterol is almost exclusively derived from endogenous biosynthesis (7). The transcription factor SREBP2 controls
the expression of enzymes involved in cholesterol biosynthesis,
including the rate-limiting enzyme HMG-CoA reductase (HMGR)
(8). In addition, the nuclear receptors LXRs control the gene expression of proteins involved in cholesterol transport (9, 10), including
apoE, ABCA1, ABCG1, and ABCG4 (11, 12). Cholesterol can be
enzymatically converted by a brain-speciﬁc enzyme, 24-hydroxylase
(CYP46A1) (13), to the oxysterol 24(S)-hydroxycholesterol (24SOH);
the concentration of 24SOH far exceeds those of other oxysterols in
the brain (14). In intact cells and in vitro, 24SOH can down-regulate
sterol synthesis (15, 16). When provided to neurons, 24SOH decreases
the secretion of Aβ (17). 24SOH levels were decreased in brain samples from patients with AD (18).
www.pnas.org/cgi/doi/10.1073/pnas.0913828107

Acyl-CoA:cholesterol acyltransferase (ACAT) converts free
cholesterol to cholesteryl esters (CEs). There are two ACAT
genes, Acat1 and Acat2 (also known as Soat1 and Soat2), with
different tissue expression patterns (19). Both are considered drug
targets for treating cardiovascular diseases. Hutter-Paier et al.
reported that treating a mouse model for AD with isotype-nonselective ACAT inhibitors substantially diminished amyloid plaque density (20, 21), suggesting that ACAT inhibitors may serve as
therapeutic agents for AD; however, it was not clear whether the
effects of the ACAT inhibitors observed were caused by inhibition
of ACAT activity and/or effects on other biological process(es) in
the mouse brain. In the current work, we undertake a combined
mouse genetic and biochemical approach to evaluate the potential
role of ACAT in AD.
Results
ACAT Expression in Mouse Brains. Whether the brain has active

ACAT enzyme was previously unknown. To examine this issue,
we prepared brain homogenates from WT, Acat1−/− (A1−) and
Acat2−/− (A2−) mice and found that WT and A2− mouse brains
contained comparable ACAT enzyme activity, whereas A1−
mouse brains contained negligible activity (Fig. 1A). Various
regions prepared from WT mouse brains, but not A1− mouse
brains, all contained active ACAT (Fig. 1B). Mouse ACAT1 is a
46-kDa protein (22). Immunoblot analysis showed that, in
homogenates prepared from mouse brain (but not from other
mouse tissues), a non-ACAT1 protein band appeared in the 46kDa region; the presence of this nonspeciﬁc band precluded us
from using immunoblotting or histochemical staining to identify
ACAT1 in the mouse brain. To unambiguously identify the
ACAT1 protein, we ﬁrst performed immunoprecipitation (IP)
experiments with detergent-solubilized WT mouse brain extracts.
The results showed that ACAT activity could be efﬁciently
immunodepleted by ACAT1-speciﬁc antibodies (i.e., A1), but not
by control antibodies (Fig. 1C). We then performed immunoblotting on the immunoprecipitates; the result showed that, in
homogenates from WT mouse brain regions, the ACAT1 antibodies speciﬁcally identiﬁed a 46-kDa protein band; this band is
absent in homogenates prepared from the adrenals and brains of
A1− mice (Fig. 1D). These results indicate that mouse brains do
express ACAT1 as the major ACAT isoenzyme.
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Cholesterol metabolism has been implicated in the pathogenesis of
several neurodegenerative diseases, including the abnormal accumulation of amyloid-β, one of the pathological hallmarks of Alzheimer
disease (AD). Acyl-CoA:cholesterol acyltransferases (ACAT1 and ACAT2)
are two enzymes that convert free cholesterol to cholesteryl esters.
ACAT inhibitors have recently emerged as promising drug candidates
for AD therapy. However, how ACAT inhibitors act in the brain has so
far remained unclear. Here we show that ACAT1 is the major functional
isoenzyme in the mouse brain. ACAT1 gene ablation (A1−) in triple
transgenic (i.e., 3XTg-AD) mice leads to more than 60% reduction in
full-length human APPswe as well as its proteolytic fragments, and
ameliorates cognitive deﬁcits. At 4 months of age, A1− causes a 32%
content increase in 24-hydroxycholesterol (24SOH), the major oxysterol
in the brain. It also causes a 65% protein content decrease in HMG-CoA
reductase (HMGR) and a 28% decrease in sterol synthesis rate in AD
mouse brains. In hippocampal neurons, A1− causes an increase in the
24SOH synthesis rate; treating hippocampal neuronal cells with 24SOH
causes rapid declines in hAPP and in HMGR protein levels. A model is
provided to explain our ﬁndings: in neurons, A1− causes increases in
cholesterol and 24SOH contents in the endoplasmic reticulum, which
cause reductions in hAPP and HMGR protein contents and lead to amelioration of amyloid pathology. Our study supports the potential of
ACAT1 as a therapeutic target for treating certain forms of AD.

Fig. 1. ACAT protein, enzyme activity, and RNA expression in mouse brains.
(A) ACAT activity in 53-d-old mouse brain homogenates and (B) ACAT
activities in various regions. Cereb, cerebellum; BrStm, brainstem; Cx, cortex;
Th, thalamus; Hp, hippocampus. (C) Immunodepletion of ACAT activity in
the WT mouse brain homogenates. IP with nonspeciﬁc rabbit IgG or with
ACAT1-speciﬁc (A1) IgG. The ACAT activities in the supernatants were
measured. (D) Identiﬁcation of A1 protein. After IP, pellets were resolved by
SDS/PAGE; A1 protein (46 kDa) was detected with polyclonal A1 antibodies.
Lysates from WT and A1− mouse adrenals were used as controls. (E) A1
mRNA distribution. Upper: Nissl staining from a 2-month-old WT mouse. Cx,
cortex; Hp, hippocampus; Am, amygdale. (Middle and Bottom) In situ
hybridizations using [32P]-ACAT1 antisense riboprobe or sense riboprobe (as
negative control). For bottom panel, brain periphery was outlined artiﬁcially. (Scale bar: 250 mm.) (F) A1 mRNA levels in WT mouse hippocampus
and cortex as measured by real-time PCR and normalized against neuroﬁlament polypeptide chain (NF120) mRNA. Data in A–D and F represent
mean ± SEM; n = 2.

To determine the ACAT1 mRNA distribution in mouse brains,
we performed in situ hybridization experiments. Both hippocampus and cortex contain ACAT1 mRNA; hippocampus
expresses a stronger signal (Fig. 1E Middle ). Other ACAT1-positive regions included choroids plexus, medial habenular nucleus,
amygdala, and rostral extension of the olfactory peduncle. We next
isolated hippocampus-rich regions and cortex-rich regions from
WT mice and compared their ACAT1 mRNA levels by real-time
PCR (primer sequences are listed in Table S1). The result showed
that ACAT1 mRNA is approximately twofold higher in hippocampus than in cortex (Fig. 1F). A separate RT-PCR experiment
using ACAT2-speciﬁc primers showed that only the thalamus-rich
region, and no other brain regions, expresses low but detectable
ACAT2 mRNA levels (Fig. S1A), conﬁrming an early report by
Anderson et al. (23), who showed in monkey brains that the
ACAT2 mRNA level was nearly undetectable.
Effect of A1− on Aβ Deposition/hAPPswe Processing and on hTau. To

investigate the effect of inactivating ACAT1 on amyloid and tau
pathologies in the triple transgenic (3XTg)-AD mice (24), we
produced Acat1−/−/AD (A1−/AD) mice by crossing the Acat1−/−
mice with the 3XTg-AD mice. The breeding scheme is described
3082 | www.pnas.org/cgi/doi/10.1073/pnas.0913828107

in Fig. S2. To examine the effect of A1− on amyloid pathology, we
ﬁrst used the human speciﬁc anti-Aβ antibody 6E10 to perform
intraneuronal immunostaining in the CA1 region of hippocampi
of 4-month-old mice. Results showed that the staining was signiﬁcantly diminished (by approximately 78%) in the A1−/AD
mice (Fig. 2A Bottom). We next used ELISA to measure the total
Aβ40 and Aβ42 levels in mouse brain homogenates at 17 months
of age. Results showed that the Aβ42 levels were signiﬁcantly
decreased (by approximately 78%) in A1−/AD mice; the Aβ40
levels were also decreased, but the difference observed was not
statistically signiﬁcant. The brains of nontransgenic (NTG) mice
did not contain measurable Aβ (Fig. 2B). We next used thioﬂavin S
to stain amyloid plaques in AD mouse brains at 17 months of age.
The results showed that, in A1−/AD mice, the amyloid plaque
load in the hippocampi was signiﬁcantly reduced (by approximately 77%; Fig. 2C); in the cortex, the amyloid plaque load in
these mice showed a trend toward decreasing (P = 0.17; Fig. S1B).
We next studied the effect of A1− on human APP processing in
4-month-old AD mice. We used the antibody 6E10 to detect fulllength APP [human APP harboring the Swedish mutation
(hAPPswe)] and its proteolytic fragments sAPPα [soluble APP
fragment produced by α-secretase cleavage (hsAPPα)] and CTFβ
[C-terminal APP fragment produced by β-secretase cleavage
(hCTFβ)]. The results showed that, in A1−/AD mice, hsAPPα and
hCTFβ levels were decreased (by approximately 67% and 37%,
respectively; Fig. 3 A, C, and D). To our surprise, the hAPP level
was also signiﬁcantly reduced (by approximately 62%; Fig. 3 A and
B). In contrast to the hAPP protein levels, there was no difference in
hAPP mRNA levels between the A1+/AD mice and the A1−/AD
mice (Fig. 3E) (primer sequences are listed in Table S1). hAPP is
synthesized in the ER in its immature form (with a molecular weight
of approximately 105 kDa); the immature form moves from the ER
to the Golgi via the secretory pathway (25) and becomes highly
glycosylated (mature form has a molecular weight of approximately
115 kDa) (26, 27). We examined the effects of A1− on the levels of
immature and mature forms of hAPP in young AD mice (at 25 d of
age). The results showed that A1− led to decrease in both forms to
approximately the same extent (by approximately 52%–54%; Fig. 3
F–I), suggesting that the effect(s) of A1− act on newly synthesized
hAPP. The AD mice express both hAPP and endogenous (mouse)
APP (mAPP). To test the possibility that A1− may affect both the

Fig. 2. Effect of A1− on Aβ pathology in AD mice. (A) Intraneuronal Aβ
(using human Aβ-speciﬁc antibody 6E10) in the hippocampal CA1 region of
male mice at 4 months (P = 0.0059; n = 4 or 5). (B) Aβ42 and Aβ40 levels
analyzed by ELISA in the forebrains of mice at 17 months. For Aβ42, P =
0.035; for Aβ40, P = 0.084; n = 5. (C) Amyloid plaque load (using thioﬂavin S
staining) in the hippocampus of 17-month-old mice; P = 0.031; n = 5. (Scale
bars: 100 μm in A and C.) Data represent mean ± SEM. *P < 0.05; **P < 0.01.
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hAPP and the mAPP levels, we used a different antibody (antiserum
369), which recognizes the C-terminal fragments of both hAPP and
mAPP (28) to investigate the total APP levels in AD mice. The
results showed that there was no detectable difference in the total
APP levels among NTG, A1+/AD, and A1−/AD mice (Fig. 3J),
indicating that, in our AD mouse strain, the hAPP is not overexpressed compared with the endogenous mouse APP protein level.
We also examined the mAPP processing in mice that do not contain
the hAPP gene. In these mice, A1− also did not affect the levels of
mAPP and its homologue APLP2 (29), or any of the proteolytic
fragments derived from mAPP (Fig. 3K). These results led us to
conclude that A1− leads to reduction in only the hAPP level, not the
mAPP level. Subtle sequence differences exist between hAPP and
mAPP, and these differences may play important roles in causing
differential fates of hAPP and mAPP (30, 31). We investigated the
effect of A1− on mutant human tau (htau) in 3XTg-AD mice. The
results showed that, at 17 months of age, no signiﬁcant change was
observed in the number of hippocampal neuroﬁbrillary tangles
between the A1+/AD and the A1−/AD mice, suggesting that A1−
may not lead to tau pathology attenuation in AD mice.

sterol synthesis rate (Fig. 4C; P = 0.04) without signiﬁcantly
changing the fatty acid synthesis rate (Fig. 4D). In mouse brains,
CE contents are reported to be very low (32). We attempted to
measure CE in A1+ mouse brains by separating the CE fraction
from the free cholesterol fraction using column chromatography

A1− Ameliorates Cognitive Deﬁcits of AD Mice. (SI Results, Fig. S3).
Effects of A1− on sterol metabolism in AD mouse brains. ACAT1 is

involved in cellular cholesterol homeostasis. We hypothesized that
A1− may cause a decrease in hAPP content by affecting sterol
metabolism in AD mouse brains. To test this possibility, we isolated the sterol fractions from A1+/AD and A1−/AD mouse
brains and analyzed them by GC/MS. The results showed that, at 4
months of age, lack of A1 caused an approximate 13% decrease in
cholesterol content (Fig. 4A; P = 0.04) and an approximate 32%
increase in 24SOH content per wet weight tissue (Fig. 4B; P =
0.007). The decrease in cholesterol content of the A1−/AD mouse
brains was conﬁrmed when a colorimetric enzyme assay kit
(Wako) was employed to determine free cholesterol. The lanosterol or desmosterol contents per milligram tissue in the A1+/AD
and A1−/AD mouse brains did not change signiﬁcantly (Fig. 4B).
Additional results showed that a lack of A1 caused an approximately 10% decrease in cholesterol content and an approximate
23% increase in 24SOH content in the 2-month-old AD mouse
brains. We next compared the relative sterol synthesis and fatty
acid synthesis rates in the brains of these mice in vivo. The results
showed that A1− caused an approximate 28% decrease in the
Bryleva et al.

Fig. 4. Sterol metabolism in A1+/AD and A1−/AD mouse forebrains; 4month-old male mice were used. (A) GC-MS analysis of cholesterol (CHOL); P =
0.04; n = 5. (B) GC-MS analysis of lanosterol (LAN), desmosterol (DES), and
24SOH. For 24SOH, P = 0.007; n = 5. (C) Sterol synthesis in vivo (P = 0.04); n = 9.
(D) Fatty acid synthesis in vivo; n = 9. (E) Esteriﬁcation of [3H]cholesterol in
mouse brains; P = 0.0009; n = 6. (F) Immunoblot analysis and (G) quantiﬁcation
of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR); P = 0.001; n = 6. (H)
Relative expression of HMGR mRNA analyzed by real-time PCR; P = 0.71; n = 6.
(I) Relative expressions of mRNAs of SRE response genes or LXR response
genes analyzed by real-time PCR. HMGR, P = 0.71; 3-hydroxy-3-methylglutaryl
CoA synthase (HMGS), P = 0.24; squalene synthase (SQS), P = 0.48; lipoprotein
receptor-related protein-1 (LRP), P = 0.35; LDL receptor (LDLR), P = 0.91; sterol
regulatory element–binding protein 2 (SREBP2), P = 0.35; sterol regulatory
element–binding protein 1 (SREBP1), P = 0.54; apolipoprotein E (APOE), P =
0.07 (i.e., the difference approached but did not reach statistical signiﬁcance);
ATP-binding cassette transporter subfamily A member 1 (ABCA1), P = 0.27;
ABCG1, P = 0.058; ABCG4, P = 0.63; cytochrome P450 46A1 (CYP46A1), P = 0.3;
n = 6. Data represent mean ± SEM. *P < 0.05; **P < 0.01; and ***P < 0.001.
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Fig. 3. Effect of A1− on human and mouse APPs (mAPP) and their cleavage products in AD and NTG mouse brains. (A) Immunoblot analysis and (B–D)
quantiﬁcation. For hAPP, P = 0.042; for hCTFβ, P = 0.017; for hsAPPα, P = 0.004. Forebrains of 4-month-old mice were used; n = 7. (E) mRNA analysis of hAPP
gene by real-time PCR; n = 6. (F) Immunoblot analysis and (G and H) quantiﬁcation of mature and immature forms of hAPP from 25-d-old AD mouse
forebrains; P = 0.019 (G) and P = 0.046 (H); n = 9. (I) For the ratio of mature to immature hAPP, P = 0.368; n = 9. (J) Immunoblot analysis and quantitation of
mouse and human APP (m+hAPP) from 4-month-old NTG and A1/AD mouse forebrains. Full-length m+hAPP is detected by using antiserum 369, which
recognizes both mouse and human APP (n = 7). (K) Immunoblot analysis and quantitation of mouse endogenous APP (mAPP) and its cleavage fragments from
2-month-old C57BL/6 mouse forebrains. Antiserum 369 was used to detect mAPP and the CTF fragments (mCTFβ and mCTFα). P = 0.168 for mAPP, P = 0.605 for
mCTFβ, and P = 0.504 for mCTFα; n = 3. Data represent mean ± SEM. *P < 0.05; **P < 0.01.

and determining the cholesterol content in CE by GC/MS after CE
is saponiﬁed. The result suggested that CE might be present at no
more than 1% of the total cholesterol mass in mouse brains. The
low level of CE prevented us from reliably measuring a value. We
used a similar procedure to determine the 24SOH ester content,
and estimated that no more than 1% of total 24SOH is esteriﬁed in
the brain. These results are consistent with the ﬁnding that ACAT
prefers to use cholesterol to various oxysterols as its enzymatic
substrate (33).
To test the functionality of ACAT1 in the intact mouse brain, we
developed a procedure to measure CE synthesis in vivo by injecting
[3H]-labeled cholesterol (as a cyclodextrin complex) into intact
mouse brains. We monitored the 3H-CE produced in A1+ and A1−
mice 3 h after injection. The result showed that, in A1+/AD mice, a
small percentage of [3H] cholesterol was converted to [3H] CE
(0.56% in 3 h); in contrast, such conversion was not detectable in the
A1−/AD mouse brains (Fig. 4E). This result demonstrates that
ACAT1 in intact mouse brains does biosynthesize CE, although at a
low rate.
The data in Fig. 4 A–C suggest that, in AD mouse brains, A1−
leads to an increased 24SOH level, which in turn leads to a downregulation of the sterol synthesis rate. Studies in cell culture have
suggested that 24SOH may down-regulate sterol synthesis by two
mechanisms: by (i) blocking transcriptional activations of
SREBP2 target genes and/or (ii) increasing the degradation rate of
HMGR protein (8). To test the ﬁrst possibility, we compared the
mRNA levels of various SREBP2 target genes in the A1+/AD and
A1−/AD mouse brains, but we failed to detect statistically signiﬁcant alterations in the expression levels of these genes (Fig. 4I)
(primer sequences are listed in Table S2). Additional results
showed that no statistically signiﬁcant alterations in the mRNA
levels of various LXR target genes occurred in the brains of mice
with or without A1 (Fig. 4I) (primer sequences are listed in Table
S2). To test the second possibility, we performed immunoblot
analysis in brain homogenates prepared from the AD mice with or
without A1. The result showed that the HMGR protein content is
decreased by approximately 65% in A1−/AD mouse brains (Fig. 4
F and G; P = 0.0009), whereas the HMGR mRNA in A1− mouse
brains was not changed (Fig. 4H). Additional results showed that,
in AD mice at 25 d of age, A1− caused an approximate 62%
decrease in HMGR protein content, demonstrating that the effect
of A1− on HMGR content occurs in mice at a young age.
Biosynthesis of 24SOH in Hippocampal Neuronal Cell Cultures. The
results described here show that A1−/AD mouse brains exhibit
elevated 24SOH levels, suggesting that, in mouse neurons, A1−
may cause an increase in the biosynthesis of 24SOH. Cultured
neurons isolated from human and mouse brains synthesize and
secrete 24SOH (13, 34). Based on these reports, we established a
hippocampal-rich neuronal cell culture system from A1+/AD and
A1−/AD mice to test this possibility. We ﬁrst monitored CE biosynthesis in these neurons by incubating them with labeled [3H]
oleic acid. Upon entering cells, [3H]oleic acid is rapidly converted
to [3H]CE by ACAT. Both the A1+ cells and the A1− cells biosynthesize CE; however, A1− cells synthesize [3H]CE at much
reduced capacity than A1+ cells (Fig. 5A). We next examined the
effect of A1− on 24SOH biosynthesis by feeding neurons with the
sterol precursor [3H]acetate for 3 h, then isolated and analyzed the
labeled sterols present in the cells and in the media. The results
showed that A1− cells exhibited a reduced trend in cholesterol
synthesis rate; the difference observed between A1+ cells and
A1− cells approached but did not reach statistical signiﬁcance
(P = 0.05; Fig. 5B Right). The 24SOH synthesis rate in A1− cells
was signiﬁcantly increased (by approximately 27%; Fig. 5C Right).
We also analyzed the [3H]sterols in the media of A1+ and A1−
cells. The result showed that the [3H]cholesterol contents were not
signiﬁcantly different (Fig. 5B Left); in contrast, the [3H]24SOH
content in the media of A1− cells was signiﬁcantly (approximately
3084 | www.pnas.org/cgi/doi/10.1073/pnas.0913828107

Fig. 5. Biosynthesis and regulatory activities of 24SOH in primary hippocampal neurons. For A–E, hippocampal neurons from A1+/AD and A1−/AD
mice were employed. (A) Cholesterol esteriﬁcation in intact cells. Cells were
cultured for 7 d; lipids in cells were extracted and analyzed by TLC; P = 0.037.
(B and C) Biosynthesis of [3H]sterols from [3H]acetate. Cells were cultured for
14 d. The lipids were analyzed by TLC. (B) [3H]Cholesterol (CHOL), P = 0.4 for
media and P = 0.05 for cells and media. (C) [3H]24(S)-hydroxycholesterol
(24SOH), P = 0.04 for media and P = 0.01 for cells and media. (D) Secretion of
newly synthesized CHOL (P = 0.38) and 24SOH (P = 0.19); n = 2. (E) Immunoblot analysis of CYP46A1. Cells were cultured for 20 d; n = 2. (F) Immunoblot analysis of hAPP and HMGR in A1+/AD hippocampal neurons
incubated with 1 μM 24SOH [delivered in ethanol (EtOH) at 0.1%] for 0.5 to
3 h. Cells were cultured for 35 d; (G) Effects of treating A1+/AD hippocampal
neurons with 1 μM or 5 μM of 24SOH for 3 h on hAPP and HMGR levels. For
5 μM 24SOH, P = 0.0003 for hAPP and P = 0.03 for HMGR. Cells were cultured
for 4 or 8 weeks; n = 3. For E–G, values were normalized against the β-actin
signal in each lane. (H) Relative expression of hAPP mRNA by real-time PCR;
n = 3. Data represent mean ± SEM. *P < 0.05; **P < 0.01.

56%) higher than in A1+ cells (Fig. 5C Left). We calculated the
percentage of total [3H]sterols secreted into the media, and found
that neurons secreted only approximately 2% of total [3H]cholesterol (Fig. 5D Left), but secreted 13% to 15% of total [3H]
24SOH into the media (Fig. 5D Right).
The results described earlier (Fig. 5C) demonstrate that A1−
causes an increased 24SOH biosynthesis rate in cultured neurons.
Mouse neurons maintained in culture express CYP46A1 as a single
53-kDa protein, which can be identiﬁed by immunoblotting (13). It
is possible that the increased synthesis of 24SOH observed in A1−
neurons may be a result of an increase in CYP46A1 protein content
in these neurons. To test this possibility, we examined CYP46A1
protein content in A1+ and A1− neurons by immunoblotting. The
results showed that the intensities of the single 53-kDa protein band
were comparable between these two cell types (Fig. 5E). This result
suggests that, in hippocampal neurons, the mechanism(s) involved
in A1−dependent increase in 24SOH synthesis may not require an
increase in CYP46A1 protein content.
24SOH Provided to AD Mouse Neurons Decreases hAPP Protein Content.

The observations made in intact A1−/AD mouse brains [i.e., an
increase in 24SOH content (Fig. 4B) and a decrease in hAPP content (Fig. 3A, B, and F–I)] suggest that 24SOH may decrease hAPP
content in neurons. To test this possibility, we treated hippocampal
neuronal culture from A1+/AD mice with 24SOH, and monitored
the hAPP protein content and the HMGR protein content in parallel. We found that 1 μM 24SOH rapidly decreased the protein
contents of both hAPP and HMGR (within 3 h; Fig. 5F). A separate
experiment showed that 1 to 5 μM 24SOH causes a rapid decrease in
hAPP protein content (Fig. 5G) without affecting its mRNA level
(Fig. 5H) (primer sequences are listed in Table S1). This result
Bryleva et al.

Discussion
Earlier work showed that when the ACAT inhibitor CP113818 or
CI-1011 was administered to mice with AD, it signiﬁcantly reduced
amyloid plaques and rescued cognitive deﬁcits, suggesting that
inhibiting ACAT may prevent and/or slow the progression of AD
(20, 35). The present work supports this hypothesis. However, close
comparison revealed that several important differences exist
between the effects of the ACAT inhibitors and the effects of A1−.
CP113818 inhibited the processing of both human APP and mouse
APP; CI-1011 decreased the mature/immature ratio of hAPP. In
contrast, A1− causes a decrease in only the full-length human APP
protein content; it does not affect the mouse APP at any level, and it
does not alter the mature/immature ratio of hAPP. In addition,
unlike the effect of A1−, CP113818 did not cause a reduction in the
full-length hAPP content (20). The differences in results raise
questions about the speciﬁcity of the ACAT inhibitors employed.
ACAT is a member of the membrane bound O-acyltransferase
enzyme family (36), which comprises 16 enzymes with similar
substrate speciﬁcity and catalytic mechanisms, but with diverse
biological functions. In addition, many ACAT inhibitors are
hydrophobic, membrane-active molecules (37). When administrated to cells, they may partition into membranes at high concentration and perturb membrane properties nonspeciﬁcally.
Although CP113818 and CI-1011 are designated as ACAT inhibitors, they may also inhibit other enzymes in the membrane bound
O-acyltransferase enzyme family and/or interfere with other biological processes. Our present work shows that inactivating the
ACAT1 gene alone is sufﬁcient to ameliorate amyloid pathology,
at least in the 3XTg-AD mouse model. In this mouse model, A1−
acts to reduce Aβ load mainly by reducing the hAPP protein content. The action of A1− is similar to that of cerebrolysin, which
reduces Aβ in an AD mouse model mainly by decreasing the hAPP
protein content (38, 39). To explain how A1− leads to hAPP
content reduction, we show that the brains of A1−/AD mice contain a signiﬁcantly greater amount of 24SOH. We then demonstrate that, in neuron-rich cultures, 24SOH added to the medium
leads to rapid decrease in hAPP protein content. How 24SOH acts
on hAPP is currently unknown. APP may be a sterol-sensing protein (40); APP contains three CRAC motifs, a consensus motif
known to bind cholesterol (41). It is possible that cholesterol and/or
oxysterol may directly interact with the hAPP protein to accelerate
its rate of degradation. Other possibilities cannot be excluded. The
AD mice used in our current study express a mutant form of hAPP.
Further investigations are required to determine whether A1− also
leads to decreases in nonmutated hAPP. We also show that, in
mouse brains, A1− causes a decrease in HMGR protein and a
decrease in cholesterol biosynthesis. Earlier, Tabas et al. (42) and
Scheek et al. (43), showed that inhibiting ACAT in macrophages or
in CHO cells increases the ER “regulatory sterol pool” that
mediates down-regulation of HMGR levels and SREBP processing. The “regulatory sterol” could be cholesterol itself and/or an
oxysterol derived from cholesterol; however, whether oxysterol(s)
play(s) important roles in regulating sterol biosynthesis in the brain
in vivo is currently debated, as reviewed by Björkhem et al. (44).
This issue can be addressed in the context of recent results from
three different research groups: Russell and coworkers (45–47)
showed that knocking out the 24-hydroxylase gene Cyp46a1 caused
a near elimination in the 24SOH content and a decrease in cholesterol turnover in the mouse brains; Cyp46a1 −/− did not affect the
amyloid pathology in an AD mouse model. In contrast, Hudry et al.
1. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and
problems on the road to therapeutics. Science 297:353–356.
2. Thinakaran G, Koo EH (2008) Amyloid precursor protein trafﬁcking, processing, and
function. J Biol Chem 283:29615–29619.
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(48) showed that over-expressing Cyp46a1 in mouse brains caused
a twofold increase in 24SOH content and signiﬁcantly ameliorated
amyloid pathology in their AD mice. Hudry et al. (48) did not
observe a reduction in the hAPP protein content; instead, they
demonstrated a decrease in hAPP processing, an increase in
SREBP2 mRNA, and no change in brain cholesterol content. Our
present results show that, in A1−/AD mice, a 32% increase in
24SOH content and signiﬁcant reductions in hAPP content and
amyloid pathology occurred. The Cyp46a1 gene knockout or
Cyp46a1 overexpression in mice might have produced compensatory effects that did not occur in the A1− mice, and vice versa; thus
it is difﬁcult to directly compare the results. Conversely, these
(apparently conﬂicting) results together suggest that 24SOH may
play an auxiliary but not an obligatory role in affecting cholesterol
metabolism and amyloid biology. Based on other evidence, Brown
and Jessup (49) have independently proposed that a given oxysterol may play auxiliary but not obligatory roles in regulating
cellular cholesterol homeostasis.
We propose a mechanistic model that links cellular cholesterol
trafﬁcking with ACAT1, CYP46A1, 24SOH synthesis, hAPP, and
HMGR at the ER (Fig. S4): in neurons, cholesterol trafﬁcking in
and out of the ER occurs. The unnecessary buildup of unesteriﬁed
cholesterol at the ER (and other membranes) is toxic (50, 51). To
minimize cholesterol accumulation, A1 located at the ER removes
a portion of ER cholesterol by converting it to CE. A1− leads to an
increase in the ER cholesterol pool and raises the substrate level
for CYP46A1 at the ER (13), and leads to an increase in 24SOH
biosynthesis in neurons. A similar scenario had previously been
suggested by Sun et al. (52). The increased 24SOH and/or cholesterol concentration in the ER leads to rapid down-regulation of
hAPP protein content, perhaps by accelerating its rate of degradation at the ER, thereby limiting its capacity to produce Aβ.
24SOH secreted by neurons can enter astrocytes and other cell
types and lead to efﬁcient down-regulation of HMGR and cholesterol biosynthesis in these cells. In summary, we attribute the
beneﬁcial effects of A1− on amyloid pathology in AD mouse
brains to increase(s) in ER cholesterol and/or 24SOH level in the
neurons. Barring the possible side effects caused by altering cholesterol metabolism in the brain, our work suggests agents that
inhibit ACAT1 enzyme activity or decrease ACAT1 gene expression may have therapeutic value for treating AD in humans.
Materials and Methods
Generation of Acat1−/−/AD (A1−/AD) and Acat2−/− /AD (A2−/AD) Mice. The Acat1−/
−
and Acat2−/− mice (53, 54) in C57BL/6 background were received from Sergio
Fazio (Nashville, TN) and Shailesh Patel (Charleston, SC), respectively. The 3XTgAD mice (AD mice) in hybrid 129/C57BL/6 background contain two mutant human
transgenes, hAPP harboring Swedish mutation (hAPPswe), and mutant htau
(htauP301L), and contain the knock-in mutant presenilin 1 (PS1M146V) (55). Breeding strategy is described in Fig. S2. Detailed methods are described in SI Text.
Statistical Analysis. Statistical comparisons were made by using a two-tailed,
unpaired Student t test. The difference was considered signiﬁcant when the P
value was less than 0.05.
ACKNOWLEDGMENTS. We thank Drs. Robert Leaton, Yasuomi Urano,
Gregory Holmes, Lorenzo Sempere, Scott Howell, Yohei Shibuya, and Paul
Huang at Dartmouth University; Barbara Tate and Jim Harwood at Pﬁzer
(New York, NY); Gregory Brewer at Southern Illinois University; Chunjiang
Yu at University of Illinois Medical Center; and Irene Cheng at National
Yang-Ming University (Taiwan, ROC) for advice during the course of this
work. We also thank Stephanie Murphy for careful editing of the manuscript. The laboratory of T.Y.C. is supported by National Institutes of Health
grant HL060306. The laboratory of N.G.S. is funded by Canadian Institutes of
Health Research grants MOP 44363 and MOP 36496.

3. Wolozin B (2004) Cholesterol and the biology of Alzheimer’s disease. Neuron 41:
7–10.
4. Jiang Q, et al. (2008) ApoE promotes the proteolytic degradation of Abeta. Neuron
58:681–693.

PNAS | February 16, 2010 | vol. 107 | no. 7 | 3085

MEDICAL SCIENCES

supports the interpretation that accumulation of 24SOH in neurons
may down-regulate hAPP protein content in vivo.

5. Wellington CL (2004) Cholesterol at the crossroads: Alzheimer’s disease and lipid
metabolism. Clin Genet 66:1–16.
6. Hartmann T (2001) Cholesterol, A beta and Alzheimer’s disease. Trends Neurosci 24
(11, Suppl)S45–S48.
7. Dietschy JM, Turley SD (2004) Thematic review series: brain lipids. Cholesterol
metabolism in the central nervous system during early development and in the
mature animal. J Lipid Res 45:1375–1397.
8. Goldstein JL, DeBose-Boyd RA, Brown MS (2006) Protein sensors for membrane
sterols. Cell 124:35–46.
9. Repa JJ, Mangelsdorf DJ (2000) The role of orphan nuclear receptors in the regulation
of cholesterol homeostasis. Annu Rev Cell Dev Biol 16:459–481.
10. Beaven SW, Tontonoz P (2006) Nuclear receptors in lipid metabolism: targeting the
heart of dyslipidemia. Annu Rev Med 57:313–329.
11. Wang N, et al. (2008) ATP-binding cassette transporters G1 and G4 mediate
cholesterol and desmosterol efﬂux to HDL and regulate sterol accumulation in the
brain. FASEB J 22:1073–1082.
12. Tarr PT, Edwards PA (2008) ABCG1 and ABCG4 are coexpressed in neurons and
astrocytes of the CNS and regulate cholesterol homeostasis through SREBP-2. J Lipid
Res 49:169–182.
13. Russell DW, Halford RW, Ramirez DM, Shah R, Kotti T (2009) Cholesterol 24hydroxylase: an enzyme of cholesterol turnover in the brain. Annu Rev Biochem 78:
1017–1040.
14. Lütjohann D, et al. (1996) Cholesterol homeostasis in human brain: evidence for an
age-dependent ﬂux of 24S-hydroxycholesterol from the brain into the circulation.
Proc Natl Acad Sci USA 93:9799–9804.
15. Song BL, Javitt NB, DeBose-Boyd RA (2005) Insig-mediated degradation of HMG CoA
reductase stimulated by lanosterol, an intermediate in the synthesis of cholesterol.
Cell Metab 1:179–189.
16. Wang Y, Muneton S, Sjövall J, Jovanovic JN, Grifﬁths WJ (2008) The effect of 24Shydroxycholesterol on cholesterol homeostasis in neurons: quantitative changes to
the cortical neuron proteome. J Proteome Res 7:1606–1614.
17. Brown J, 3rd, et al. (2004) Differential expression of cholesterol hydroxylases in
Alzheimer’s disease. J Biol Chem 279:34674–34681.
18. Heverin M, et al. (2004) Changes in the levels of cerebral and extracerebral sterols in
the brain of patients with Alzheimer’s disease. J Lipid Res 45:186–193.
19. Chang TY, Li BL, Chang CC, Urano Y (2009) Acyl-coenzyme A:cholesterol
acyltransferases. Am J Physiol Endocrinol Metab 297:E1–E9.
20. Hutter-Paier B, et al. (2004) The ACAT inhibitor CP-113,818 markedly reduces amyloid
pathology in a mouse model of Alzheimer’s disease. Neuron 44:227–238.
21. Huttunen HJ, Kovacs DM (2008) ACAT as a drug target for Alzheimer’s disease.
Neurodegener Dis 5:212–214.
22. Meiner V, et al. (1997) Tissue expression studies on the mouse acyl-CoA: cholesterol
acyltransferase gene (Acact): ﬁndings supporting the existence of multiple cholesterol
esteriﬁcation enzymes in mice. J Lipid Res 38:1928–1933.
23. Anderson RA, et al. (1998) Identiﬁcation of a form of acyl-CoA:cholesterol
acyltransferase speciﬁc to liver and intestine in nonhuman primates. J Biol Chem 273:
26747–26754.
24. Morrissette DA, Parachikova A, Green KN, LaFerla FM (2009) Relevance of transgenic
mouse models to human Alzheimer disease. J Biol Chem 284:6033–6037.
25. Cai D, et al. (2003) Presenilin-1 regulates intracellular trafﬁcking and cell surface
delivery of beta-amyloid precursor protein. J Biol Chem 278:3446–3454.
26. Weidemann A, et al. (1989) Identiﬁcation, biogenesis, and localization of precursors
of Alzheimer’s disease A4 amyloid protein. Cell 57:115–126.
27. Oltersdorf T, et al. (1990) The Alzheimer amyloid precursor protein. Identiﬁcation of a
stable intermediate in the biosynthetic/degradative pathway. J Biol Chem 265:
4492–4497.
28. Buxbaum JD, et al. (1990) Processing of Alzheimer beta/A4 amyloid precursor protein:
modulation by agents that regulate protein phosphorylation. Proc Natl Acad Sci USA
87:6003–6006.
29. Slunt HH, et al. (1994) Expression of a ubiquitous, cross-reactive homologue of the
mouse beta-amyloid precursor protein (APP). J Biol Chem 269:2637–2644.
30. Du P, et al. (2007) Dominance of amyloid precursor protein sequence over host cell
secretases in determining beta-amyloid proﬁles studies of interspecies variation and
drug action by internally standardized immunoprecipitation/mass spectrometry. J
Pharmacol Exp Ther 320:1144–1152.

3086 | www.pnas.org/cgi/doi/10.1073/pnas.0913828107

31. Muhammad A, et al. (2008) Retromer deﬁciency observed in Alzheimer’s disease
causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. Proc
Natl Acad Sci USA 105:7327–7332.
32. Liu B, et al. (2009) Reversal of defective lysosomal transport in NPC disease
ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse. Proc Natl
Acad Sci USA 106:2377–2382.
33. Liu J, Chang CC, Westover EJ, Covey DF, Chang TY (2005) Investigating the allosterism
of acyl-CoA:cholesterol acyltransferase (ACAT) by using various sterols: in vitro and
intact cell studies. Biochem J 391:389–397.
34. Kim WS, et al. (2007) Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol
efﬂux to apolipoprotein E discs and suppression of amyloid-beta peptide generation.
J Biol Chem 282:2851–2861.
35. Huttunen HJ, et al. (2009) Inhibition of acyl-coenzyme A: cholesterol acyl transferase
modulates amyloid precursor protein trafﬁcking in the early secretory pathway.
FASEB J 23:3819–3828.
36. Hofmann K (2000) A superfamily of membrane-bound O-acyltransferases with
implications for wnt signaling. Trends Biochem Sci 25:111–112.
37. Homan R, Hamelehle KL (2001) Inﬂuence of membrane partitioning on inhibitors of
membrane-bound enzymes. J Pharm Sci 90:1859–1867.
38. Rockenstein E, et al. (2006) Cerebrolysin decreases amyloid-beta production by
regulating amyloid protein precursor maturation in a transgenic model of
Alzheimer’s disease. J Neurosci Res 83:1252–1261.
39. Rockenstein E, et al. (2007) Effects of Cerebrolysin on neurogenesis in an APP
transgenic model of Alzheimer’s disease. Acta Neuropathol 113:265–275.
40. Beel AJ, et al. (2008) Structural studies of the transmembrane C-terminal domain of
the amyloid precursor protein (APP): does APP function as a cholesterol sensor?
Biochemistry 47:9428–9446.
41. Epand RM (2008) Proteins and cholesterol-rich domains. Biochim Biophys Acta 1778:
1576–1582.
42. Tabas I, Weiland DA, Tall AR (1986) Inhibition of acyl coenzyme A:cholesterol acyl
transferase in J774 macrophages enhances down-regulation of the low density
lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzyme A reductase and
prevents low density lipoprotein-induced cholesterol accumulation. J Biol Chem 261:
3147–3155.
43. Scheek S, Brown MS, Goldstein JL (1997) Sphingomyelin depletion in cultured cells
blocks proteolysis of sterol regulatory element binding proteins at site 1. Proc Natl
Acad Sci USA 94:11179–11183.
44. Björkhem I (2009) Are side-chain oxidized oxysterols regulators also in vivo? J Lipid
Res 50 (Suppl):S213–S218.
45. Lund EG, et al. (2003) Knockout of the cholesterol 24-hydroxylase gene in mice reveals
a brain-speciﬁc mechanism of cholesterol turnover. J Biol Chem 278:22980–22988.
46. Kotti TJ, Ramirez DM, Pfeiffer BE, Huber KM, Russell DW (2006) Brain cholesterol
turnover required for geranylgeraniol production and learning in mice. Proc Natl
Acad Sci USA 103:3869–3874.
47. Halford RW, Russell DW (2009) Reduction of cholesterol synthesis in the mouse brain
does not affect amyloid formation in Alzheimer’s disease, but does extend lifespan.
Proc Natl Acad Sci USA 106:3502–3506.
48. Hudry E, et al. (2009) Adeno-associated virus gene therapy with cholesterol 24hydroxylase reduces the amyloid pathology before or after the onset of amyloid
plaques in mouse models of Alzheimer’s disease. Mol Ther.
49. Brown AJ, Jessup W (2009) Oxysterols: sources, cellular storage and metabolism, and
new insights into their roles in cholesterol homeostasis. Mol Aspects Med 30:111–122.
50. Warner GJ, Stoudt G, Bamberger M, Johnson WJ, Rothblat GH (1995) Cell toxicity
induced by inhibition of acyl coenzyme A:cholesterol acyltransferase and accumulation
of unesteriﬁed cholesterol. J Biol Chem 270:5772–5778.
51. Tabas I (2002) Consequences of cellular cholesterol accumulation: basic concepts and
physiological implications. J Clin Invest 110:905–911.
52. Sun Y, Yao J, Kim TW, Tall AR (2003) Expression of liver X receptor target genes
decreases cellular amyloid beta peptide secretion. J Biol Chem 278:27688–27694.
53. Meiner VL, et al. (1996) Disruption of the acyl-CoA:cholesterol acyltransferase gene in
mice: evidence suggesting multiple cholesterol esteriﬁcation enzymes in mammals.
Proc Natl Acad Sci USA 93:14041–14046.
54. Buhman KK, et al. (2000) Resistance to diet-induced hypercholesterolemia and
gallstone formation in ACAT2-deﬁcient mice. Nat Med 6:1341–1347.
55. Oddo S, et al. (2003) Triple-transgenic model of Alzheimer’s disease with plaques and
tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:409–421.

Bryleva et al.

